-+ 0.00%
-+ 0.00%
-+ 0.00%

Evercore ISI Group Maintains Outperform on Travere Therapeutics, Raises Price Target to $60

Benzinga·06/18/2026 15:27:26
Listen to the news
Evercore ISI Group analyst Liisa Bayko maintains Travere Therapeutics (NASDAQ:TVTX) with a Outperform and raises the price target from $52 to $60.